NCT05887999CompletedPhase 1
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
A Phase 1, Randomized, Placebo-Controlled, 2-Period, Cross-over, Double- Blind, Single-Dose Study to Evaluate the Effects of LY3532226 on Insulin- Induced Hypoglycemia in Participants With Type 1 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 26 Mar 2024
Brief summary (registry, in English)
The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM). The study will also evaluate if LY3532226 helped participants to recover from insulin-induced low blood sugar condition compared to placebo. The study will last approximately 16 weeks excluding screening period.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 25 May 2023
- Start date
- 12 Jun 2023
- Primary completion date
- 21 Feb 2024
- Lead sponsor
- Eli Lilly and Company
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT05887999
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- From 12 Jun 2023 to the primary completion date, 21 Feb 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have received systemic or inhaled glucocorticoid therapy
- Are currently taking part in another clinical study trial involving medical research, or have participated within the last 30 days of screening in a clinical study involving a study intervention
Lab values
- Have been treated with dipeptidyl peptidase-Ni, GLP-1 receptor agonists, GIP agonists, metformin or sodium-glucose cotransporter 2 inhibitors within the previous 3 months
Other
- Have acute proliferative retinopathy requiring active treatment within 3 months of screening
- Women of childbearing potential
Who the study is looking for
- Participants with type 1 diabetes mellitus (T1DM) for at least 2 years treated with insulin
- Body mass index (BMI) of 18.5 to 40.0 kilograms per meter squared (kg/m²)
- Are males or females not of childbearing potential
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ProSciento, Inc. Coordinator of this site? Confirm its status | Chula Vista | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.